The Newborn Screening Quality Assurance Program. W. Harry Hannon, Ph.D. Chief, Newborn Screening Branch Centers for Disease Control and Prevention.

Slides:



Advertisements
Similar presentations
Mass Screening Using Tandem Mass Spectrometry: Friend or Foe?
Advertisements

CAP/POCT 2003 Carol Riley-Hunte, RRT Senior Education Specialist Bayer HealthCare.
Point of Care Testing BOPCC May 31, 2011 Beatrice OKeefe, Chief Laboratory Field Services California Department of Public Health.
Why Lab. Certification? Laboratory certification tries to insure that the laboratory is qualified and capable of analyzing the sample and obtaining quality.
Newborn Screening in Texas Jann Melton-Kissel Susan U. Neill.
Day 2 You receive 2 reports on your desk –The first describes the possibility of expanding the states newborn screening panel to include Severe Combined.
Anne Sholander, MT(ASCP), International QA/QC Coordinator, SMILE
The Clinic for Special Children Where compassion, care, and bioinformatics result in cutting edge translational medicine.
QUALITY CONTROL IN HEMATOLOGY
The Joint Commission Chapter update: Waived Testing
UNDERSTANDING ENVIRONMENTAL LABORATORY/QC REPORTS Maya Murshak – Merit Laboratories, Inc.
Tandem Mass Spectrometry QA/QC for Newborn Screening: Routine Operations. Mark A. Morrissey, PhD Wadsworth Center Department of Health State of New York.
Tandem MS Newborn Screening
UAB Metabolomics Symposium December 12, 2012 Christopher B. Newgard, Ph.D. Sarah W. Stedman Nutrition and Metabolism Center Department of Pharmacology.
1 Proposed Rule: Amendments to the Protocol Gas Verification Program and Minimum Competency Requirements for Air Emission Testing Presented at May 12,
Newborn Screening Overview Marie Mann, M.D., M.P.H. U.S. Department of Health and Human Services Health Resources and Services Administration Maternal.
Prepared by Jane Hibbert on behalf of the Regional ANCH Screening Teams Expanded Newborn Screening Pilot 16th July 2012 – 19th July 2013 NIHR CLAHRC for.
Genetic testing Biochemical genetic testing Cytogenetic testing Direct genetic testing Diagnostic testing Predictive testing Carrier testing Prenatal testing.
Preliminary studies Imperfect bloodspots – what matters for the screening laboratory? UK Newborn Screening Laboratories Network Alex Lawson* Kate Hall.
National Center for Environmental Health Centers for Disease Control and Prevention Carla D. Cuthbert, Ph.D. Chief, Newborn Screening and Molecular Biology.
Hallauer 06/20011 Outcome evaluation of an universal hepatitis B immunisation programme Johannes F. Hallauer M.D. Health Systems Research Charité, Humboldt.
Overview of Newborn Screening Laboratory Processes and Quality Management Scott M. Shone, PhD Program Manager New Jersey NBS Laboratory SACHDNC May 11,
Footnotes available in notes section. Source: National Newborn Screening and Genetics Resource Center. Retrieved May 14, 2014, from
Region 4 Genetics Collaborative NCC/RC Annual Meeting November 17, 2009 Region 4 Genetics Collaborative Long-term Follow-up Projects.
Competency/Training and CLIA
Internal Quality Control (QC) for Medical Laboratories: An introduction Dr. Otto Panagiotakis and Dr. Alexander Haliassos ESEAP – Greek Proficiency Testing.
The Newborn Screening System
Tandem Mass Spectrometry Newborn Screening Quality Assurance and Control Instrument and Method Validation Gary Hoffman Wisconsin Newborn Screening Laboratory.
Unit #7 - Basic Quality Control for the Clinical Laboratory
1. Dr. Adel M. Assiri Faculty of Medicine Department of Biochemistry Umm Al-Qura University.
National Center for Environmental Health Centers for Disease Control and Prevention Suzanne Cordovado, Ph.D. Team Lead, Molecular Quality Improvement Program.
Pregnancy & Newborn Screening Developments Medium Chain Acyl CoA Dehydrogenase Deficiency (MCADD)
Unit 8 Presentation Chapter 17
I have no relevant financial relationships with the manufacturers of any commercial products and/or provider of commercial services discussed in this CME.
1 Meeting Children’s Special Food and Nutrition Needs in Child Nutrition Programs Lesson 4: Understanding Inborn Errors of Metabolism Define inborn errors.
Prof. of Clinical Chemistry, Mansoura University.
Apheresis Blood Components
Newborn Screening in Wisconsin Jill Paradowski RN, MS Newborn Screening Coordinator Southeast region of Wisconsin.
Christopher N. Greene, PhD Newborn Screening and Molecular Biology Branch, Division of Laboratory Sciences NCEH, CDC Tuesday, 28th June 2011 Molecular.
Leukocyte-Reduced Blood Components Lore Fields MT(ASCP)SBB Consumer Safety Officer, DBA, OBRR, CBER September 16, 2009.
FEEDBACK QUESTIONNAIRE Frequency of samples Sample volume Appropriateness of analyte concentrations Adequacy of the report Website display Usefulness.
· Lecture 31 & 32 : Scope of clinical biochemistry ط Uses of clinical biochemistry tests ط Diagnosis, Prognosis, Screening, Monitoring ط Reporting results.
Laboratory Certification Update Part 2 Common Findings KWWOA Louisville April 15, 2015 Presented by Frank Hall, Laboratory Certification Coordinator.
Quality control & Statistics. Definition: it is the science of gathering, analyzing, interpreting and representing data. Example: introduction a new test.
BACKGROUND The ERNDIM qualitative acylcarnitine external QA scheme circulates dried blood spots from patients with metabolic disease detectable by acylcarnitine.
PT/External Quality Assessment Principles & Concepts Dr Marjan R. Farzami
Methodology Results Amino Acid Levels in Newborns A Pilot Study on an Expanded Newborn Screening Program in Palestine Samir Khatib, Amer Ayyad Medical.
NEWBORN SCREENING Greg Enns, MB, ChB, FAAP Professor of Pediatrics
Hemoglobin Device Regulation Josephine Bautista, M.S., MT (ASCP) Senior Advisor for IVD Regulation DRB/DBA/OBRR/CBER Workshop: Hemoglobin standards and.
CLIA Waiver for the OraQuick ® Rapid HIV-1 Antibody Test Elliot P. Cowan, Ph.D. Senior Regulatory Scientist Office of Blood Research and Review Center.
TEXAS NEWBORN SCREEN PRESENTED BY: SHAYNA BAUMAN & ROSA CARRANZA UNIVERSITY OF TEXAS MEDICAL BRANCH AT GALVESTON ADVANCED NEONATAL HEALTH ASSESSMENT GNRS.
Newborn screening Doc. MUDr. Marie Černá, CSc. Lecture No 423-H.
LECTURE 13 QUALITY ASSURANCE METHOD VALIDATION
Center for Surveillance, Epidemiology, and Laboratory Services Division of Health Informatics and Surveillance 1 eSHARE Webinar: Jurisdiction Onboarding.
UNCERTAINTY OF MEASUREMENT Andrew Pascall Technical Director Integral Laboratories (Pty) Ltd
MCADD, caused by mutation in the ACADM gene is the most common disorder of fatty acid  - oxidation. Treatment is very successfully if started before symptoms.
HuQAS Proficiency testing Scheme - A necessity in continuous quality improvement Michael Kamiru
Introduction to Quality Assurance. Quality assurance vs. Quality control.
Lesson 1-9 Quality Assessment.
Quality Assurance Procedure Manuals.
NEONATAL SCREENING M.Prasad Naidu MSc Medical Biochemistry,
Unit #6 - Basic Quality Control for the Clinical Laboratory
Introduction to Lab Quality
Point of Care Testing California Clinical Laboratory Association
Complying With CLIA Competency Requirements
Practical clinical chemistry
NEWBORN SCREENING IN THE UK
Uncertainty of measurement – practical relevance and the results of the DBS scheme Prof Jim Bonham Clinical Director Sheffield Children’s NHS FT 1.
Quality System Considerations for Over-The-Counter HIV Testing
Quality Assessment The goal of laboratory analysis is to provide the accurate, reliable and timeliness result Quality assurance The overall program that.
Presentation transcript:

The Newborn Screening Quality Assurance Program

W. Harry Hannon, Ph.D. Chief, Newborn Screening Branch Centers for Disease Control and Prevention

 Quality (QC) control materials  Proficiency testing (PT) panels and evaluations  Training, consultations, network resources  Technical help  Follow-up by a CDC lab scientist for false-negative reports  Additional dried blood spot specimens can be provided for repeats for repeats Filter paper evaluations for pre-distribution certification  Filter paper evaluations for pre-distribution certification  Reference materials  Start-up materials: blood spot reference materials, archived QC materials, and previously distributed PT specimens Quality Assurance Services provided by NSQAP:

On April 13, 2001, a report was published in the MMWR Vol. 50 No. RR-3 with recommendations for using Tandem Mass Spectrometry for Metabolic Disease Screening using dried blood spots. This document contains valuable information about laboratory practice, follow-up, diagnosis, and treatment proposals. MMWR Morbidity and Mortality Weekly Report April 13, 2001/Vol. 50/No. RR-3

DISORDER OF AMINO ACID METABOLISM PhenylketonuriaPhe Maple syrup urine diseaseLeu/Ile, Val HomocystinuriaMet HypermethioninemiaMet CitrullinemiaCit Argininosuccinic aciduriaCit TyrosinemiaTyr

DISORDERS OF FATTY ACID METABOLISM Medium-chain acyl-CoA dehydrogenase deficiencyC8, C6, C10, C10:1, Very-long-chain acyl-CoA dehydrogenase deficiencyC14:1, C14, C16 Short-chain acyl-CoA dehydrogenase deficiencyC4 Multiple acyl-CoA dehydrogenase deficiencyC4, C5, C8:1, C8, C12, C14, C16, C5DC Carnitine palmitoyl transferase deficiencyC16, C18:1, C18 Carnitine/acylcarnitine translocase defectC16, C18:1, C18 Long-chain hydroxy acyl-CoA dehydrogenase deficiencyC16OH, C18:1OH, C18OH Trifunctional protein deficiency C16OH, C18:1OH, C18OH

DISORDERS OF ORGANIC ACID METABOLISM Glutaric acidemia Type 1C5DC Propionic acidemiaC3 Methylmalonic acidemiaC3 Isovaleric acidemiaC5 3-hydroxy-3-methylglutaryl CoA lyase deficiencyC5OH 3-methylcrotonyl-CoA carboxylase deficiencyC5OH

Amino Acid Reference Materials for Phe, Leu, Met, Tyr, and Val described in Clinical Chemistry 1999;45:

Amino Acid Reference Materials (AARMS) for Start-Up n=12

BLOOD MATRIX: each set made from a single multi-donor batch of pooled red cells and clarified serum; hematocrit adjusted to 55%+1%; frozen before use to hemolyze red blood cells. SET DESCRIPTION: each set contains a non-enriched pool for measurement of endogenous levels and three pools enriched with low, medium, and high levels of amino acids or acylcarnitines. AMINO ACID ENRICHMENTS: each set enriched with Phe, Leu, Met, Tyr, Val, and Cit. ACYLCARNITNE ENRICHMENTS: each set enriched with C2, C3, C4, C5, C5DC, C6, C8, C10, C14, and C16. DRIED BLOOD SPOT QUALITY CONTROL MATERIALS

ENRICHMENTS OF ACYLCARNITINES QUALITY CONTROL MATERIALS (  mol/L whole blood) Analyte Lot 365 Lot 366 Lot 367 Lot 368 C C C C C5DC 0 -- C C C C C

Annual programs must provide minimum of 5 specimens per testing event – NSQAP provides five specimens. Must be at least 3 testing events at equal intervals during the year - NSQAP has 4 events per year, one per quarter. Specimens must simulate the unknown test sample - NSQAP specimen matrix: whole blood adjusted to a newborn hematocrit. Specimens must cover the clinically relevant range of values or clinical significance - NSQAP enriches specimens with analyte concentrations that are typical of real disease states. Specimens may be distributed by Federal Express or mail - NSQAP sends all packages by FedEx with tracking. Assess the accuracy of the laboratory’s response (grading) in accordance with specified criteria – NSQAP provides instructions with codes for the assessment grading. 42 Code of Federal Regulations (CFR), 430.0, October 2000 A Model CLIA Certified Proficiency Testing Program

PROFICIENCY TESTING (PT) Participation usually a regulatory requirement for labs that report patient specimen results Provides an external measure of the total system Uses blind-coded samples: normal and disorder/range Evaluates performance of the moment only/snapshot Meets requirements for certification

Means and Ranges of Acylcarnitine Cutoff Values Reported by Domestic MS/MS Laboratories Mean Cutoff  mol/L blood Source: Quarter 3, 2003 NSQAP Data C3 C4 C5 C6 C8 C10 C14 C16 C5DC N Represents a wide spread of reported cutoff values N = Number of laboratories reporting their cutoff values Min/Max

Distribution of Propionylcarnitine (C3) Cutoff Values among Participating Laboratories Source: Quarter 3, 2003 NSQAP MS/MS Data

Amino Acid Mean Cutoff Values Reported by MS/MS Laboratories Min/Max mg/dL Mean Cutoff Value mg/dL blood Phenylalanine Leucine Methionine Tyrosine Valine Citrulline N = Number of laboratories reporting their cutoff value Wide min/max cutoff range N Source: Quarter 3, 2003 NSQAP MS/MS Data

Distribution of Tyrosine Cutoff Values among Participating Laboratories Source: Quarter 3, 2003 NSQAP MS/MS Data

How Can Labs Use NSQAP for MS/MS Start-up? Enroll in NSQAP PT program as soon as MS/MS instrument start-up begins. Request previous quarter’s PT specimens and report. Request supplies of archived QC materials for instrument comparison and performance monitoring. Request Reference Materials for method calibration and assessments of method linearity. View the 2003 MS/MS annual report online at Contact Connie Singleton at or at for enrollment and to request materials.